A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants

What Was Tested

This registered phase 1 trial tested Orforglipron (Foundayo, non-peptide).

The main purpose of this study is to assess and compare a single capsule and multiple capsules of Orforglipron based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants under fasted and fed conditions.

How the body handles and eliminates the study drug after meals and on an empty stomach will be measured.

Information about any adverse effects experienced will be collected and the safety and tolerability of Orforglipron will also be evaluated.

It had 1 arm (groups): Orforglipron (experimental).

The registry classes the interventions as drug.

Who Took Part

86 actual participants took part.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Have venous access sufficient to allow for blood sampling. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.

How the Study Was Run

It was run as a randomized, crossover and open-label study.

Because people in this Orforglipron (Foundayo, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Orforglipron (Foundayo, non-peptide) and the comparison at some point, usually with a gap in between.

Being open-label, the Orforglipron (Foundayo, non-peptide) study did not mask who received what.

It started in 2024-12-13 with completion listed for 2025-06-09.

It ran at 3 sites in Japan (3).

Its stated primary purpose is basic science.

What Was Measured

Primary outcome: PK: Steady-state Maximum Concentration (Cmax) of Orforglipron (Fasted State) (time frame: Week 3 Through Week 16). PK: Steady-state AUC of Orforglipron (Fed State) (time frame: Week 3 Through Week 16). PK: Steady-state Cmax of Orforglipron (Fed State) (time frame: Week 3 Through Week 16).

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Orforglipron (Foundayo, non-peptide) in 86 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.